Damora Therapeutics (DMRA) Net Income towards Common Stockholders (2019 - 2026)

Damora Therapeutics has reported Net Income towards Common Stockholders for 8 years, with the latest figure at -$27.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 996.84% year-over-year to -$27.8 million; the trailing twelve-month figure through Mar 2026 stood at -$231.2 million (down 3133.97% YoY), and the FY2025 full-year result was -$206.0 million, down 1940.61% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$27.8 million, up from -$196.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $4.6 million in Q4 2024, with the low at -$196.9 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$20.2 million across 5 years, with a median of -$8.1 million in 2023.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 171.1% — and 2025, when it slumped 4376.19%.
• Damora Therapeutics' Net Income towards Common Stockholders stood at -$13.5 million in 2022, then surged by 52.13% to -$6.5 million in 2023, then soared by 171.1% to $4.6 million in 2024, then tumbled by 4376.19% to -$196.9 million in 2025, then soared by 85.89% to -$27.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$27.8 million (Q1 2026), -$196.9 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.